Aaron Wealth Advisors LLC Sells 20,033 Shares of 10x Genomics $TXG

Aaron Wealth Advisors LLC decreased its stake in shares of 10x Genomics (NASDAQ:TXG) by 30.2% during the first quarter, HoldingsChannel.com reports. The fund owned 46,381 shares of the company’s stock after selling 20,033 shares during the period. Aaron Wealth Advisors LLC’s holdings in 10x Genomics were worth $985,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Geneos Wealth Management Inc. bought a new stake in shares of 10x Genomics in the fourth quarter valued at approximately $38,000. Larson Financial Group LLC increased its stake in 10x Genomics by 164.4% during the fourth quarter. Larson Financial Group LLC now owns 2,364 shares of the company’s stock valued at $39,000 after acquiring an additional 1,470 shares during the period. Van ECK Associates Corp raised its holdings in 10x Genomics by 85.9% in the 4th quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock valued at $60,000 after acquiring an additional 1,695 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of 10x Genomics by 203.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock worth $87,000 after acquiring an additional 5,025 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of 10x Genomics by 28.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,660 shares of the company’s stock worth $92,000 after purchasing an additional 1,237 shares in the last quarter. 84.68% of the stock is owned by institutional investors.

10x Genomics Stock Performance

Shares of TXG stock opened at $36.75 on Friday. The firm’s 50 day moving average price is $26.65 and its two-hundred day moving average price is $22.07. 10x Genomics has a 52-week low of $11.16 and a 52-week high of $37.05. The stock has a market cap of $4.67 billion, a PE ratio of -216.18 and a beta of 2.12.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.19. 10x Genomics had a negative return on equity of 2.86% and a negative net margin of 3.55%.The business had revenue of $150.84 million for the quarter, compared to analyst estimates of $146.41 million. During the same period last year, the company earned ($0.28) EPS. The firm’s revenue was up 9.4% on a year-over-year basis. As a group, sell-side analysts predict that 10x Genomics will post -0.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In other 10x Genomics news, CEO Serge Saxonov sold 30,000 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $34.44, for a total transaction of $1,033,200.00. Following the transaction, the chief executive officer owned 1,108,380 shares in the company, valued at approximately $38,172,607.20. This trade represents a 2.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Shehnaaz Suliman sold 5,723 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $32.63, for a total value of $186,741.49. Following the completion of the sale, the director directly owned 31,722 shares of the company’s stock, valued at approximately $1,035,088.86. This trade represents a 15.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 96,309 shares of company stock worth $2,704,157. Corporate insiders own 8.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TXG. Bank of America upped their target price on 10x Genomics from $21.00 to $30.00 and gave the company a “neutral” rating in a research note on Monday, April 20th. JPMorgan Chase & Co. boosted their price target on shares of 10x Genomics from $17.00 to $20.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. Barclays increased their price objective on shares of 10x Genomics from $30.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 10x Genomics in a report on Wednesday. Finally, Morgan Stanley upped their target price on shares of 10x Genomics from $20.00 to $22.00 and gave the company an “equal weight” rating in a research note on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $24.00.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.